Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zebrafish | 14 | 2025 | 97 | 4.780 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2020 | 13 | 3.320 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2021 | 8 | 2.450 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2018 | 42 | 1.570 |
Why?
|
| B-Lymphocytes | 3 | 2024 | 279 | 1.530 |
Why?
|
| Animals, Genetically Modified | 9 | 2025 | 54 | 1.260 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 114 | 1.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 375 | 0.940 |
Why?
|
| Thymus Gland | 1 | 2024 | 53 | 0.890 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2018 | 12 | 0.850 |
Why?
|
| Cell Lineage | 2 | 2019 | 45 | 0.780 |
Why?
|
| Lymphoma, B-Cell | 2 | 2018 | 18 | 0.720 |
Why?
|
| Green Fluorescent Proteins | 2 | 2019 | 100 | 0.700 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 445 | 0.690 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 57 | 0.680 |
Why?
|
| Hypertriglyceridemia | 1 | 2019 | 8 | 0.660 |
Why?
|
| Animals | 14 | 2025 | 10082 | 0.650 |
Why?
|
| Dyslipidemias | 1 | 2019 | 31 | 0.640 |
Why?
|
| Cell Separation | 1 | 2019 | 55 | 0.630 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 106 | 0.620 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2021 | 38 | 0.610 |
Why?
|
| Lymphopoiesis | 1 | 2018 | 22 | 0.610 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 27 | 0.600 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 161 | 0.590 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 280 | 0.570 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 544 | 0.540 |
Why?
|
| Databases, Factual | 1 | 2017 | 253 | 0.510 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 22 | 0.510 |
Why?
|
| Humans | 20 | 2024 | 27175 | 0.490 |
Why?
|
| Microsporida | 1 | 2014 | 1 | 0.460 |
Why?
|
| Fish Diseases | 1 | 2014 | 4 | 0.460 |
Why?
|
| Microsporidiosis | 1 | 2014 | 4 | 0.450 |
Why?
|
| Granuloma | 1 | 2014 | 18 | 0.450 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 1271 | 0.440 |
Why?
|
| Necrosis | 1 | 2014 | 81 | 0.440 |
Why?
|
| Translocation, Genetic | 2 | 2011 | 22 | 0.430 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2020 | 20 | 0.410 |
Why?
|
| Burkitt Lymphoma | 3 | 2018 | 4 | 0.390 |
Why?
|
| Genomics | 2 | 2020 | 116 | 0.390 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 666 | 0.380 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2011 | 1 | 0.370 |
Why?
|
| Cell Differentiation | 3 | 2024 | 398 | 0.340 |
Why?
|
| Transgenes | 1 | 2009 | 59 | 0.320 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2020 | 140 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 189 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 438 | 0.260 |
Why?
|
| Child | 6 | 2021 | 2163 | 0.260 |
Why?
|
| Lymphoid Tissue | 1 | 2025 | 9 | 0.240 |
Why?
|
| Lymphatic Vessels | 1 | 2025 | 20 | 0.240 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 1406 | 0.240 |
Why?
|
| Lymphocytes | 1 | 2024 | 83 | 0.230 |
Why?
|
| Biopsy | 1 | 2024 | 202 | 0.220 |
Why?
|
| Models, Animal | 1 | 2024 | 128 | 0.220 |
Why?
|
| Male | 7 | 2021 | 13034 | 0.220 |
Why?
|
| Incidence | 2 | 2019 | 553 | 0.210 |
Why?
|
| Phenotype | 2 | 2019 | 667 | 0.210 |
Why?
|
| Adolescent | 4 | 2018 | 2996 | 0.200 |
Why?
|
| Child, Preschool | 3 | 2016 | 1101 | 0.190 |
Why?
|
| Female | 7 | 2021 | 14658 | 0.180 |
Why?
|
| Rituximab | 2 | 2018 | 60 | 0.180 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2020 | 3 | 0.180 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 74 | 0.170 |
Why?
|
| Immunotherapy | 2 | 2018 | 139 | 0.160 |
Why?
|
| Pedigree | 1 | 2019 | 154 | 0.160 |
Why?
|
| India | 1 | 2019 | 139 | 0.160 |
Why?
|
| Flow Cytometry | 2 | 2011 | 285 | 0.160 |
Why?
|
| Genetic Testing | 1 | 2019 | 64 | 0.160 |
Why?
|
| Injections, Spinal | 1 | 2018 | 7 | 0.150 |
Why?
|
| Consolidation Chemotherapy | 2 | 2015 | 2 | 0.150 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 134 | 0.150 |
Why?
|
| Prognosis | 2 | 2021 | 762 | 0.150 |
Why?
|
| Web Browser | 1 | 2017 | 4 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2019 | 708 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2013 | 659 | 0.140 |
Why?
|
| Leukemia, T-Cell | 1 | 2016 | 2 | 0.130 |
Why?
|
| Leukemia, B-Cell | 1 | 2016 | 3 | 0.130 |
Why?
|
| Molecular Biology | 1 | 2016 | 16 | 0.130 |
Why?
|
| Mutation | 1 | 2019 | 823 | 0.120 |
Why?
|
| Cytarabine | 2 | 2014 | 4 | 0.120 |
Why?
|
| Vincristine | 2 | 2014 | 9 | 0.120 |
Why?
|
| Methotrexate | 2 | 2014 | 31 | 0.120 |
Why?
|
| Prednisone | 2 | 2014 | 51 | 0.120 |
Why?
|
| Cyclophosphamide | 2 | 2014 | 37 | 0.120 |
Why?
|
| Doxorubicin | 2 | 2014 | 74 | 0.120 |
Why?
|
| Biomarkers | 1 | 2017 | 736 | 0.110 |
Why?
|
| Immunoglobulin Light Chains, Surrogate | 1 | 2013 | 1 | 0.110 |
Why?
|
| Rhabdoid Tumor | 1 | 2013 | 9 | 0.110 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2013 | 3 | 0.110 |
Why?
|
| Teratoma | 1 | 2013 | 17 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 262 | 0.110 |
Why?
|
| United States | 1 | 2019 | 2063 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 163 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 50 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2013 | 62 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 93 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2013 | 121 | 0.100 |
Why?
|
| Hydrazones | 1 | 2012 | 3 | 0.100 |
Why?
|
| Leukemia | 1 | 2012 | 23 | 0.100 |
Why?
|
| Quinolines | 1 | 2012 | 25 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2018 | 2289 | 0.100 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 60 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 5 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 88 | 0.090 |
Why?
|
| Genome | 1 | 2011 | 53 | 0.090 |
Why?
|
| Mutagenesis | 1 | 2009 | 45 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 66 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 622 | 0.080 |
Why?
|
| Young Adult | 1 | 2016 | 2636 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 324 | 0.080 |
Why?
|
| Middle Aged | 1 | 2019 | 6918 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2009 | 647 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2006 | 4 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2006 | 12 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 2006 | 14 | 0.070 |
Why?
|
| Axilla | 1 | 2025 | 2 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2025 | 98 | 0.060 |
Why?
|
| Ikaros Transcription Factor | 1 | 2021 | 9 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 154 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2013 | 567 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2021 | 115 | 0.050 |
Why?
|
| Gene Transfer Techniques | 1 | 2020 | 66 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 864 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 30 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 129 | 0.030 |
Why?
|
| Typhlitis | 1 | 2014 | 1 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 9 | 0.030 |
Why?
|
| Etoposide | 1 | 2014 | 19 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2014 | 15 | 0.030 |
Why?
|
| Remission Induction | 1 | 2014 | 50 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 99 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 41 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 218 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 76 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 225 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2013 | 9 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2013 | 30 | 0.030 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2013 | 13 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 398 | 0.030 |
Why?
|
| Blast Crisis | 1 | 2012 | 1 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 128 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 76 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 134 | 0.020 |
Why?
|
| Mitosis | 1 | 2012 | 109 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 250 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 458 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 738 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2006 | 4 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2006 | 17 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 72 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 1374 | 0.020 |
Why?
|
| Adult | 1 | 2015 | 7510 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 4472 | 0.010 |
Why?
|